A new study put Eli Lilly's Zepbound and Novo Nordisk's Wegovy to the test. Here's which one will help you lose more weight.

Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Christmas has come early for Eli Lilly this year, courtesy of a fresh FDA approval for the Indianapolis drugmaker’s obesity ...

Weight loss with Ozempic or Wegovy can come with nausea, but avoiding certain foods and drinks can help patients manage the ...

The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes.

Novo Nordisk faces scrutiny after disappointing trial results for CagriSema, a next-gen obesity drug, caused a significant market valuation drop. Analysts question whether side effects limited dosage ...

An experimental Novo Nordisk anti-obesity treatment helped patients lose less than a quarter of their bodyweight in a new ...

Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to ...

Although Novo underscored that patients in the trial achieved up to 22.7% of weight loss with CagriSema, analysts previously said they were hoping to see whether it would significantly beat Lilly’s ...

Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of ...